Dermatological Clinic, Department of Biostatistics and Medical Information Technology Polytechnic Marche University, Via Conca 71, Ancona, Italy.
Am J Clin Dermatol. 2010;11 Suppl 1:46-8. doi: 10.2165/1153424-S0-000000000-00000.
Psoriasis is a chronic, immune-mediated, inflammatory dermatosis whose aetiopathogenesis remains unclear, although tumour necrosis factor alpha (TNFalpha) appears to play a crucial role. The biological potential of TNFalpha inhibitors, such as etanercept, which reduce the inflammatory cascade, has radically changed the therapeutic management of patients with psoriasis and other immunomediated inflammatory diseases, associated with TNFalpha. The pathogenesis of the selective destruction of melanocytes in vitiligo is not fully understood, although there is growing evidence that several T helper type 1 cytokines, particularly TNFalpha, may be involved in the depigmentation process. A patient is described who presented with both psoriasis and vitiligo, and was treated with etanercept. After 24 weeks of therapy, the patient's psoriasis had improved markedly and the patient noted a mild improvement of vitiligo, with a reduction in macules and repigmentation in the scapular region.
银屑病是一种慢性、免疫介导的炎症性皮肤病，其发病机制尚不清楚，尽管肿瘤坏死因子-α（TNFα）似乎起着至关重要的作用。TNFα 抑制剂（如依那西普）的生物学潜力可减少炎症级联反应，这极大地改变了银屑病和其他与 TNFα 相关的免疫介导的炎症性疾病患者的治疗管理。尽管越来越多的证据表明，几种辅助性 T 细胞 1 型细胞因子，尤其是 TNFα，可能参与了色素脱失过程，但白癜风中黑素细胞选择性破坏的发病机制仍不完全清楚。本文描述了一位同时患有银屑病和白癜风的患者，该患者接受了依那西普治疗。经过 24 周的治疗，患者的银屑病明显改善，患者注意到白癜风有轻度改善，肩胛区的斑块减少并出现复色。
